Aptose Biosciences Inc. logo
Aptose to Participate in Two Biotech Events in January 2022
December 29, 2021 07:30 ET | Aptose Biosciences, Inc.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....
Aptose Biosciences Inc. logo
Aptose Provides Update on APTO-253 Program
December 20, 2021 07:30 ET | Aptose Biosciences, Inc.
-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE)...
Aptose Biosciences Inc. logo
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
December 13, 2021 16:30 ET | Aptose Biosciences, Inc.
HM43239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO,...
Aptose Biosciences Inc. logo
Aptose to Hold Corporate Update Monday, December 13th
November 29, 2021 07:30 ET | Aptose Biosciences, Inc.
HM43239 clinical update in AML after oral presentation at 2021 ASH Annual MeetingLuxeptinib clinical update in AML and B-cell cancers SAN DIEGO and TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Aptose...
Aptose Biosciences Inc. logo
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 22, 2021 16:02 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Reports Results for the Third Quarter 2021
November 11, 2021 16:01 ET | Aptose Biosciences, Inc.
- Conference call and webcast at 5:00 pm ET today - - HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline - - HM43239 phase 1/2 study in AML advances to 200...
Aptose Biosciences Inc. logo
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
November 04, 2021 09:00 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Biosciences Inc. logo
Aptose Enters into Exclusive Worldwide License Agreement with Hanmi Pharmaceutical for Clinical-Stage Myeloid Kinome Inhibitor HM43239
November 04, 2021 06:00 ET | Aptose Biosciences, Inc.
HM43239 delivers multiple complete responses (CRs) in diverse R/R AML patients Aptose to host conference call and webcast today at 9:00 am ET SAN DIEGO and TORONTO and SEOUL, South Korea, Nov. 04,...
Aptose Biosciences Inc. logo
Aptose to Report Third Quarter 2021 Financial Results and Hold Conference Call on Thursday, November 11, 2021
October 26, 2021 07:30 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
Aptose Biosciences Inc. logo
Aptose Expands Senior Leadership Team
October 25, 2021 08:00 ET | Aptose Biosciences, Inc.
Janet Clennett, CPA, appointed Vice President, Finance Roger Davies, B.Sc., M. Phil, joins as Vice President, Operations SAN DIEGO and TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences...